Zepbound bests Wegovy for weight loss in new trial

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Source: Medical Xpress

Read more